Page 1

GenSight BIOLOGICS GenSight Biologics Announces its 2021 Financial Calendar Press Release Paris , France , January 18 , 2021 , 5.45 pm CET · GenSight Biologics ( Euronext : SIGHT , ISIN : FR0013183985 , PEA - PME eligible ) , a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders , today announced its financial calendar for 2021 . Information 2020 4Q Cash Position 2020 Full - Year Financial Update and Statements 2021 1Q Cash Position Annual General Meeting 2021 First - Half Financial Update and Statements 2021 3Q Cash Position 2021 4Q Cash Position Date * January 19 , 2021 March 10 , 2021 April 20 , 2021 April 29 , 2021 July 29 , 2021 October 19 , 2021 January 18 , 2022 * This financial calendar is provided for information only and may be subject to changes . The Company's updated financial calendar is available on its corporate website . Contacts GenSight Biologics Chief Financial Officer Thomas Gidoin tgidoin@gensight-biologics.com +33 ( 0 ) 1 76 21 72 20 LifeSci Advisors Investor Relations Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 ( 0 ) 76 735 01 31 About GenSight Biologics RooneyPartners Media Relations Marion Janic mjanic@rooneyco.com + 1-646-537-5649 Orpheon Finance Retail Investors James Palmer j.palmer@orpheonfinance.com +33 ( 0 ) 7 60 92 77 74 GenSight Biologics S.A. is a clinical - stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders . GenSight Biologics ' pipeline leverages two core technology platforms , the Mitochondrial Targeting Sequence ( MTS ) and optogenetics , to help preserve or restore vision in patients suffering from blinding retinal diseases . Using its gene therapy - based approach , GenSight Biologics ' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery . Developed as a treatment for Leber Hereditary Optic Neuropathy ( LHON ) , GenSight Biologics ' lead product candidate , LUMEVOQ® ( GS010 ; lenadogene nolparvovec ) , is currently in the review phase of its registration process in Europe , and in Phase III to move forward to a BLA filing in the U.S.